Quality of life in non-melanoma skin cancer

Australasian Journal of Dermatology

Volumn 56, Issue 1, 2015, Pages 70-76

  Gaulin, Charles ^a   Sebaratnam, Deshan F ^a,b,c   Fernández Peñas, Pablo ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

Author keywords

basal cell carcinoma; quality of life; skin cancer index; Skindex; squamous cell carcinoma; time trade off; utility; utility weighting; willingness to pay

Indexed keywords

BASAL CELL CARCINOMA; CHEMOSURGERY; COST EFFECTIVENESS ANALYSIS; CURETTAGE; DAILY LIFE ACTIVITY; DERMATOLOGY LIFE QUALITY INDEX; EXCISION; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; NON MELANOMA SKIN CANCER; PHYSICIAN; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; RESOURCE ALLOCATION; REVIEW; SCORING SYSTEM; SHORT FORM 12; SHORT FORM 36; SICKNESS IMPACT PROFILE; SKIN CANCER INDEX; SKIN SURGERY; SKINDEX 16; SQUAMOUS CELL CARCINOMA; VISUAL ANALOG SCALE; PSYCHOLOGY; SKIN TUMOR;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; QUALITY OF LIFE; SKIN NEOPLASMS; SURVEYS AND QUESTIONNAIRES;

EID: 84923806752     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12205     Document Type: Review

References (36)

1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (US), Center for Biologics Evaluation and Research (US), Center for Devices and Radiological Health (US). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009.
2. Rhee JS, Loberiza FR, Matthews BA, et al. Quality of life assessment in nonmelanoma cervicofacial skin cancer. Laryngoscope 2003; 113: 215-220.
3. Chren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J. Cutan. Med. Surg. 2001; 5: 105-110.
4. Chen SC, Bayoumi AM, Soon SL, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. J. Investig. Dermatol. Symp. Proc. 2004; 9: 160-168.
5. Rhee JS, Matthews BA, Neuburg M, et al. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399-405.
6. Davis RE, Spencer JM,. Basal and squamous cancer of the facial skin. Curr. Opin. Otolaryngol. Head Neck Surg. 1997; 5: 86-92.
7. Fessa CK, Man Ying Tsang V, Fenández-Peñas P,. Relationship between visibility of skin condition and quality of life. Australas. J. Dermatol. 2011; 52 (S2): 11.
8. Coates E, Chee SN, Lowe PM,. Dermatological challenges in solid organ transplant recipients: the first 18 months of a dedicated transplant dermatology database. Australas. J. Dermatol. 2013; 54 (S2): 36.
9. Essers B, Nieman F, Prins M, et al. Perceptions of facial aesthetics in surgical patients with basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2007; 21: 1209-1214.
10. Chren MM,. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol. Clin. 2012; 30: 231-236.
11. Gold MR,. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
12. Drummond F, Torrance GW,. Methods for the Economic Evaluation of Health Care Programs. Oxford: Oxford University Press, 2005.
13. Blackford S, Roberts D, Salek MS, et al. Basal cell carcinomas cause little handicap. Qual. Life Res. 1996; 5: 191-194.
14. Steinbauer J, Koller M, Kohl E, et al. Quality of life in health care of non-melanoma skin cancer-results of a pilot study. J. Dtsch Dermatol. Ges. 2011; 9: 129-135.
15. Chren MM, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J. Invest. Dermatol. 2007; 127: 1351-1357.
16. Chen T, Bertenthal D, Sahay A, et al. Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. Arch. Dermatol. 2007; 143: 1386-1392.
17. Rhee JS, Matthews BA, Neuburg M, et al. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol. Surg. 2004; 30 (4 Pt 1): 525-529.
18. Shah M, Coates M,. An assessment of the quality of life in older patients with skin disease. Br. J. Dermatol. 2006; 154: 150-153.
19. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br. Med. J. 1992; 305: 160-164.
20. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 1981; 19: 787-805.
21. Finlay AY, Khan GY,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994; 19: 210-216.
22. Rhee JS, Matthews BA, Neuburg M, et al. Quality of life and sun-protective behavior in patients with skin cancer. Arch. Otolaryngol. Head Neck Surg. 2004; 130: 141-146.
23. Kemppainen JK,. Predictors of quality of life in AIDS patients. J. Assoc. Nurses AIDS Care 2001; 12: 61-70.
24. Rumsfeld JS, Ho PM, Magid DJ, et al. Predictors of health-related quality of life after coronary artery bypass surgery. Ann. Thorac. Surg. 2004; 77: 1508-1513.
25. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983; 67: 361-370.
26. Weinman J, Petrie KJ, Moss-morris, R, et al. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. Psychol. Health 1996; 11: 431-445.
27. Rhee JS, Matthews BA, Neuburg M, et al. Creation of a quality of life instrument for nonmelanoma skin cancer patients. Laryngoscope 2005; 115: 1178-1185.
28. Rhee JS, Matthews BA, Neuburg M, et al. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch. Facial Plast. Surg. 2006; 8: 314-318.
29. Burdon-Jones D, Thomas P, Baker R,. Quality of life issues in nonmetastatic skin cancer. Br. J. Dermatol. 2010; 162: 147-151.
30. Lee EH, Klassen AF, Nehal KS, et al. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. J. Am. Acad. Dermatol. 2013; 69: e59-67.
31. Seidler AM, Bayoumi AM, Goldstein MK, et al. Willingness to pay in dermatology: assessment of the burden of skin diseases. J. Invest. Dermatol. 2012; 132: 1785-1790.
32. Lear W, Akeroyd JE, Mittmann N, et al. Measurement of utility in nonmelanoma skin cancer. J. Cutan. Med. Surg. 2008; 12: 102-106.
33. Seidler AM, Bramlette TB, Washington CV, et al. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol. Surg. 2009; 35: 1776-1787.
34. Shingler SL, Garside J, Samanta K, et al. Utilities for advanced basal cell carcinoma. J. Med. Econ. 2013; 16: 777-783.
35. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009; 361: 1164-1172.
36. Gaulin C, Sebaratnam DF, Fernández-Peñas P,. Quality of life in non-melanoma skin cancer. Australas. J. Dermatol. 2013; 54 (S3): 8.